Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLIFY-DCB
jRCTs051250093Recruiting
- Sponsor
- Nipro Corporation
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of clopidogrel and aspirin in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Nipro Corporation. Primary endpoint: Composite clinical and bleeding endpoint at 12 months. Started Aug 2025; status: recruiting.
02
Drugs
clopidogrelaspirin
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on jRCTs051250093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250093.